Circulating Tumor Cells: from New Biological Insights to Clinical Practice

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2024 Sep 1

PMID 39218931

Authors

Xuyu Gu

Shiyou Wei

Xin Lv

Affiliations

Soon will be listed here.

Abstract

The primary reason for high mortality rates among cancer patients is metastasis, where tumor cells migrate through the bloodstream from the original site to other parts of the body. Recent advancements in technology have significantly enhanced our comprehension of the mechanisms behind the bloodborne spread of circulating tumor cells (CTCs). One critical process, DNA methylation, regulates gene expression and chromosome stability, thus maintaining dynamic equilibrium in the body. Global hypomethylation and locus-specific hypermethylation are examples of changes in DNA methylation patterns that are pivotal to carcinogenesis. This comprehensive review first provides an overview of the various processes that contribute to the formation of CTCs, including epithelial-mesenchymal transition (EMT), immune surveillance, and colonization. We then conduct an in-depth analysis of how modifications in DNA methylation within CTCs impact each of these critical stages during CTC dissemination. Furthermore, we explored potential clinical implications of changes in DNA methylation in CTCs for patients with cancer. By understanding these epigenetic modifications, we can gain insights into the metastatic process and identify new biomarkers for early detection, prognosis, and targeted therapies. This review aims to bridge the gap between basic research and clinical application, highlighting the significance of DNA methylation in the context of cancer metastasis and offering new avenues for improving patient outcomes.

Citing Articles

Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.

Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).

PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.

Traditional Chinese medicine in lung cancer treatment.

Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H Mol Cancer. 2025; 24(1):57.

PMID: 40001110 PMC: 11863959. DOI: 10.1186/s12943-025-02245-6.

Appendiceal cancer in pregnancy and circulating tumor cells detection in the umbilical cord.

Kudo R, Matsumoto K, Ishiguro T, Sekizuka T, Nishijima K, Enomoto T Heliyon. 2025; 11(3):e42411.

PMID: 39991232 PMC: 11847105. DOI: 10.1016/j.heliyon.2025.e42411.

Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.

Li W, Luo P, Chen Q, Cheng L, Gan L, Zhang F Front Immunol. 2025; 16:1518144.

PMID: 39981244 PMC: 11841399. DOI: 10.3389/fimmu.2025.1518144.

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells.

Ito F, Iwata W, Adachi Y, Sesaki H, Iijima M Front Cell Dev Biol. 2025; 12:1511190.

PMID: 39897079 PMC: 11782226. DOI: 10.3389/fcell.2024.1511190.

References

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Kebede A, Schneider R, Daujat S . Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest. FEBS J. 2014; 282(9):1658-74. DOI: 10.1111/febs.13047. View

Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P . A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology. 2021; 161(6):2053-2056.e2. DOI: 10.1053/j.gastro.2021.08.054. View

Lucci A, Hall C, Patel S, Narendran B, Bauldry J, Royal R . Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020; 26(8):1886-1895. DOI: 10.1158/1078-0432.CCR-19-2670. View

Russell J, Monga S . Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. Annu Rev Pathol. 2017; 13:351-378. PMC: 5927358. DOI: 10.1146/annurev-pathol-020117-044010. View

Lu M, Zhu W, Wang X, Tang J, Zhang K, Yu G . ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. Cell Metab. 2019; 29(4):886-900.e5. DOI: 10.1016/j.cmet.2018.12.019. View

Hynes W, Pepona M, Robertson C, Alvarado J, Dubbin K, Triplett M . Examining metastatic behavior within 3D bioprinted vasculature for the validation of a 3D computational flow model. Sci Adv. 2020; 6(35):eabb3308. PMC: 7449690. DOI: 10.1126/sciadv.abb3308. View

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V . hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-78. DOI: 10.1016/j.cell.2005.02.020. View

10.

Gall T, Belete S, Khanderia E, Frampton A, Jiao L . Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. Am J Pathol. 2018; 189(1):71-81. DOI: 10.1016/j.ajpath.2018.03.020. View

11.

Feng M, Xu H, Zhou W, Pan Y . The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023; 42(1):44. PMC: 9909925. DOI: 10.1186/s13046-023-02615-2. View

12.

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

13.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

14.

Haynes B, Telen M, Hale L, Denning S . CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol Today. 1989; 10(12):423-8. DOI: 10.1016/0167-5699(89)90040-6. View

15.

Beck B, Driessens G, Goossens S, Youssef K, Kuchnio A, Caauwe A . A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 2011; 478(7369):399-403. DOI: 10.1038/nature10525. View

16.

Barros-Filho M, Marchi F, Pinto C, Rogatto S, Kowalski L . High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2015; 100(6):E890-9. DOI: 10.1210/jc.2014-4053. View

17.

Strauss R, Li Z, Liu Y, Beyer I, Persson J, Sova P . Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011; 6(1):e16186. PMC: 3021543. DOI: 10.1371/journal.pone.0016186. View

18.

Roperch J, Incitti R, Forbin S, Bard F, Mansour H, Mesli F . Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013; 13:566. PMC: 4219483. DOI: 10.1186/1471-2407-13-566. View

19.

Visal T, den Hollander P, Cristofanilli M, Mani S . Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. Br J Cancer. 2022; 127(2):173-184. PMC: 9296521. DOI: 10.1038/s41416-022-01768-9. View

20.

Zhang K, Zhu W, Wang S, Gao C, Pan J, Du Z . Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021; 11(13):6560-6572. PMC: 8120208. DOI: 10.7150/thno.55609. View